2017 Q4 Form 10-K Financial Statement

#000106282219000007 Filed on March 15, 2019

View on sec.gov

Income Statement

Concept 2017 Q4 2017 Q3 2017 Q2
Revenue $33.97M $27.67M $12.09M
YoY Change 47.44% -0.16% -39.83%
Cost Of Revenue $500.0K $599.0K $537.0K
YoY Change
Gross Profit $33.90M $27.08M $11.55M
YoY Change -2.32% -42.51%
Gross Profit Margin 99.81% 97.84% 95.56%
Selling, General & Admin $16.00M $16.72M $18.48M
YoY Change 13.48% 36.38% 119.52%
% of Gross Profit 47.2% 61.77% 159.96%
Research & Development $42.60M $39.14M $26.93M
YoY Change 62.6% -25.5% -44.14%
% of Gross Profit 125.66% 144.55% 233.19%
Depreciation & Amortization $900.0K $900.0K $1.000M
YoY Change 50.0% 80.0% 100.0%
% of Gross Profit 2.65% 3.32% 8.66%
Operating Expenses $58.60M $56.46M $45.95M
YoY Change 45.41% -9.88% -19.55%
Operating Profit -$29.02M -$28.61M -$33.49M
YoY Change -7.39% -18.11% -9.54%
Interest Expense -$2.200M $1.619M $1.614M
YoY Change 37.5% -1.64% -1.47%
% of Operating Profit
Other Income/Expense, Net $600.0K $415.0K $448.0K
YoY Change 20.0% -26.42% -18.1%
Pretax Income -$26.30M -$30.72M -$35.06M
YoY Change 17.41% -14.7% -8.01%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$26.61M -$29.81M -$34.66M
YoY Change -17.92% -17.23% -9.07%
Net Earnings / Revenue -78.34% -107.71% -286.73%
Basic Earnings Per Share
Diluted Earnings Per Share -$211.2K -$290.7K -$333.3K
COMMON SHARES
Basic Shares Outstanding 105.6M shares 105.6M shares 105.2M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2017 Q4 2017 Q3 2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $310.8M $196.8M $231.2M
YoY Change -10.3% -50.25% -46.16%
Cash & Equivalents $61.66M $83.29M $30.71M
Short-Term Investments $249.1M $113.5M $200.5M
Other Short-Term Assets $4.434M $4.458M $10.17M
YoY Change 14.34% 82.48% 12.16%
Inventory $1.948M $2.149M $811.0K
Prepaid Expenses
Receivables $4.825M $10.60M $5.014M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $322.0M $214.0M $247.2M
YoY Change -10.03% -46.33% -43.75%
LONG-TERM ASSETS
Property, Plant & Equipment $17.69M $18.17M $18.59M
YoY Change -8.78% -8.5% -8.66%
Goodwill $44.54M $44.54M $44.54M
YoY Change 0.0% 0.0% 0.0%
Intangibles $51.89M $52.33M $52.77M
YoY Change -2.76% -1.93% -1.1%
Long-Term Investments
YoY Change
Other Assets $429.0K $429.0K $428.0K
YoY Change -6.94% -5.51% -0.47%
Total Long-Term Assets $114.5M $115.5M $116.3M
YoY Change -2.72% -2.32% -1.98%
TOTAL ASSETS
Total Short-Term Assets $322.0M $214.0M $247.2M
Total Long-Term Assets $114.5M $115.5M $116.3M
Total Assets $436.5M $329.5M $363.5M
YoY Change -8.22% -36.26% -34.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $38.76M $52.63M $43.86M
YoY Change -26.69% 26.68% 55.38%
Accrued Expenses $12.28M $12.73M $10.96M
YoY Change -61.75% -61.32% -54.24%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $14.09M $14.63M $15.16M
YoY Change -13.43% -12.86% -12.34%
Total Short-Term Liabilities $105.5M $128.7M $133.2M
YoY Change -35.93% -24.33% 1.66%
LONG-TERM LIABILITIES
Long-Term Debt $231.6M $85.51M $85.38M
YoY Change 171.91% 0.56% 0.56%
Other Long-Term Liabilities $292.0K $303.0K $313.0K
YoY Change -63.73% -87.88% -97.77%
Total Long-Term Liabilities $231.9M $85.82M $85.70M
YoY Change 169.7% -1.97% -13.39%
TOTAL LIABILITIES
Total Short-Term Liabilities $105.5M $128.7M $133.2M
Total Long-Term Liabilities $231.9M $85.82M $85.70M
Total Liabilities $368.3M $251.1M $257.2M
YoY Change 15.73% -24.31% -24.53%
SHAREHOLDERS EQUITY
Retained Earnings -$1.365B -$1.353B -$1.322B
YoY Change 9.19% 11.09% 11.88%
Common Stock $106.0K $106.0K $105.0K
YoY Change 0.95% 1.92% 0.96%
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.904M $1.904M $1.904M
YoY Change -43.47% -43.47% -43.47%
Treasury Stock Shares 122.0K shares 122.0K shares 122.0K shares
Shareholders Equity $68.27M $78.38M $106.3M
YoY Change
Total Liabilities & Shareholders Equity $436.5M $329.5M $363.5M
YoY Change -8.22% -36.26% -34.87%

Cashflow Statement

Concept 2017 Q4 2017 Q3 2017 Q2
OPERATING ACTIVITIES
Net Income -$26.61M -$29.81M -$34.66M
YoY Change -17.92% -17.23% -9.07%
Depreciation, Depletion And Amortization $900.0K $900.0K $1.000M
YoY Change 50.0% 80.0% 100.0%
Cash From Operating Activities -$33.70M -$34.00M -$32.20M
YoY Change -30.94% -3.41% -32.78%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00 -$100.0K
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$135.7M $87.10M $56.90M
YoY Change -339.75% 156.93% -7.63%
Cash From Investing Activities -$135.8M $87.10M $56.70M
YoY Change -340.35% 156.93% -7.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 147.8M -500.0K 3.700M
YoY Change 73800.0% -129.41%
NET CHANGE
Cash From Operating Activities -33.70M -34.00M -32.20M
Cash From Investing Activities -135.8M 87.10M 56.70M
Cash From Financing Activities 147.8M -500.0K 3.700M
Net Change In Cash -21.70M 52.60M 28.20M
YoY Change -374.68% 13050.0% 107.35%
FREE CASH FLOW
Cash From Operating Activities -$33.70M -$34.00M -$32.20M
Capital Expenditures $0.00 $0.00 -$100.0K
Free Cash Flow -$33.70M -$34.00M -$32.10M
YoY Change -30.8% -3.41% -32.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018 dei Amendment Flag
AmendmentFlag
false
CY2018 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2018 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2018 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
CY2018 dei Document Period End Date
DocumentPeriodEndDate
2018-12-31
CY2018 dei Document Type
DocumentType
10-K
CY2018 dei Entity Central Index Key
EntityCentralIndexKey
0001062822
CY2019Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
106271927 shares
CY2018 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2018 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2018 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2018Q2 dei Entity Public Float
EntityPublicFloat
491500000 USD
CY2018 dei Entity Registrant Name
EntityRegistrantName
LEXICON PHARMACEUTICALS, INC./DE
CY2018 dei Entity Shell Company
EntityShellCompany
false
CY2018 dei Entity Small Business
EntitySmallBusiness
false
CY2018 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2018 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2017Q1 lxrx Accumulated Excess Tax Benefits Recognizedas Deferred Tax Assets
AccumulatedExcessTaxBenefitsRecognizedasDeferredTaxAssets
6100000 USD
CY2017Q1 lxrx Adjustmentto Accumulated Deficit
AdjustmenttoAccumulatedDeficit
2000000 USD
CY2001Q3 lxrx Coelacanth Purchase Price
CoelacanthPurchasePrice
36000000 USD
CY2018Q4 lxrx Convertible Debt Instrument Interest Rate Stated Percentage
ConvertibleDebtInstrumentInterestRateStatedPercentage
0.0525
CY2018Q4 lxrx Deferred Tax Assetremeasured
DeferredTaxAssetremeasured
165300000 USD
CY2018 lxrx Cost Of Goods And Services Sold Period Reflecting Lower Average Per Unit Cost Of Materials
CostOfGoodsAndServicesSoldPeriodReflectingLowerAveragePerUnitCostOfMaterials
P18M
CY2018 lxrx Debt Instrument Repurchase Percentage
DebtInstrumentRepurchasePercentage
1
CY2018Q4 lxrx Buildings Collateral
BuildingsCollateral
59200000 USD
CY2016 lxrx Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
-703000 USD
CY2017 lxrx Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
2101000 USD
CY2018 lxrx Change In Fair Value Of Symphony Icon Inc Purchase Liability
ChangeInFairValueOfSymphonyIconIncPurchaseLiability
0 USD
CY2001Q3 lxrx Coelacanth Goodwill
CoelacanthGoodwill
25800000 USD
CY2017Q4 lxrx Deferred Tax Assets Section163j Lxrx
DeferredTaxAssetsSection163j_LXRX
0 USD
CY2017Q4 lxrx Deferred Tax Assets Tax Credit Carryforwards Orphan Drug
DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug
24524000 USD
CY2018Q4 lxrx Deferred Tax Assets Tax Credit Carryforwards Orphan Drug
DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrug
24524000 USD
CY2017Q4 lxrx Deferred Tax Liability Related To Acquisition Of Symphony Icon
DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon
10896000 USD
CY2018Q4 lxrx Deferred Tax Liability Related To Acquisition Of Symphony Icon
DeferredTaxLiabilityRelatedToAcquisitionOfSymphonyIcon
10525000 USD
CY2018Q4 lxrx Deferred Tax Liabilityfrom Reclassified Indefinitelived Intangible
DeferredTaxLiabilityfromReclassifiedIndefinitelivedIntangible
4000000 USD
CY2017Q1 lxrx Deferred Tax Liabilityfrom Reclassified Intangible Asset
DeferredTaxLiabilityfromReclassifiedIntangibleAsset
8700000 USD
CY2018 lxrx Defined Contribution Plan Requisite Service Period
DefinedContributionPlanRequisiteServicePeriod
P4Y
CY2016 lxrx Disclosure On Geographic Areas Revenue From External Customers Attributed To Entitys Country Of Domicile Percent
DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent
0.01
CY2017 lxrx Disclosure On Geographic Areas Revenue From External Customers Attributed To Entitys Country Of Domicile Percent
DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent
0.17
CY2018 lxrx Disclosure On Geographic Areas Revenue From External Customers Attributed To Entitys Country Of Domicile Percent
DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedToEntitysCountryOfDomicilePercent
0.40
CY2016 lxrx Disclosure On Geographic Areas Revenue From External Customers Attributedto France
DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance
0.99
CY2017 lxrx Disclosure On Geographic Areas Revenue From External Customers Attributedto France
DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance
0.83
CY2018 lxrx Disclosure On Geographic Areas Revenue From External Customers Attributedto France
DisclosureOnGeographicAreasRevenueFromExternalCustomersAttributedtoFrance
0.60
CY2017 lxrx Entity Wide Revenue Ipsen Percentage
EntityWideRevenueIpsenPercentage
0.18
CY2016 lxrx Entity Wide Revenue Sanofi Percentage
EntityWideRevenueSanofiPercentage
0.90
CY2017 lxrx Entity Wide Revenue Sanofi Percentage
EntityWideRevenueSanofiPercentage
0.66
CY2018 lxrx Entity Wide Revenue Sanofi Percentage
EntityWideRevenueSanofiPercentage
0.53
CY2007Q2 lxrx Holdings Contribution To Icon
HoldingsContributionToIcon
45000000 USD
CY2014Q4 lxrx Ipsen Maximum Regulatory And Commercial Milestones
IpsenMaximumRegulatoryAndCommercialMilestones
11800000 USD
CY2014Q4 lxrx Ipsen Maximum Sales Milestones
IpsenMaximumSalesMilestones
72000000 EUR
CY2016Q3 lxrx Ipsen Milestone Payment Received
IpsenMilestonePaymentReceived
6400000 USD
CY2017Q4 lxrx Ipsen Milestone Payment Received
IpsenMilestonePaymentReceived
3800000 USD
CY2017Q4 lxrx Ipsen Milestone Payment Received
IpsenMilestonePaymentReceived
3800000 USD
CY2018Q4 lxrx Ipsen Milestone Payment Received
IpsenMilestonePaymentReceived
1300000 USD
CY2018Q3 lxrx Ipsen Milestone Payment Received
IpsenMilestonePaymentReceived
5100000 USD
CY2014Q4 lxrx Ipsen Revenue Allocatedto Committee Deliverable
IpsenRevenueAllocatedtoCommitteeDeliverable
100000 USD
CY2014Q4 lxrx Ipsen Revenue Allocatedto Development Deliverable
IpsenRevenueAllocatedtoDevelopmentDeliverable
1700000 USD
CY2014Q4 lxrx Ipsen Revenue Allocatedto License Deliverable
IpsenRevenueAllocatedtoLicenseDeliverable
21200000 USD
CY2017 lxrx Ipsen Revenue Allocatedto License Deliverable
IpsenRevenueAllocatedtoLicenseDeliverable
1400000 USD
CY2016 lxrx Ipsen Revenue Recognized
IpsenRevenueRecognized
7200000 USD
CY2017 lxrx Ipsen Revenue Recognized
IpsenRevenueRecognized
16200000 USD
CY2018 lxrx Ipsen Revenue Recognized
IpsenRevenueRecognized
4600000 USD
CY2017 lxrx Ipsen Royalty Income Lxrx
IpsenRoyaltyIncome_LXRX
100000 USD
CY2018 lxrx Ipsen Royalty Income Lxrx
IpsenRoyaltyIncome_LXRX
300000 USD
CY2018Q4 lxrx Ipsen Total Payments To Date
IpsenTotalPaymentsToDate
45000000 USD
CY2014Q4 lxrx Ipsen Total Upfront Payments
IpsenTotalUpfrontPayments
24500000 USD
CY2017 lxrx Ipsenproductsales
Ipsenproductsales
800000 USD
CY2018 lxrx Ipsenproductsales
Ipsenproductsales
1600000 USD
CY2018 lxrx Lxrx Biologicscustomerconcentration
LXRXBiologicscustomerconcentration
0.25
CY2018 lxrx Lxrx Diplomatcustomerconcentration
LXRXDiplomatcustomerconcentration
0.14
CY2018Q4 lxrx Land Collateral
LandCollateral
2700000 USD
CY2010Q3 lxrx Lexicon Paid Holdings Cash
LexiconPaidHoldingsCash
10000000 USD
CY2007Q2 lxrx Lexicon Received Cash From Holdings
LexiconReceivedCashFromHoldings
15000000 USD
CY2007Q2 lxrx Lexicon Sold Shares To Holdings
LexiconSoldSharesToHoldings
1092946 shares
CY2018Q3 lxrx Mortgage Debt Balloon Payment Lxrx
MortgageDebtBalloonPayment_LXRX
10300000 USD
CY2018Q3 lxrx Mortgage Debt Instrument Revere Lxrx
MortgageDebtInstrument_Revere_LXRX
12900000 USD
CY2018Q3 lxrx Mortgage Debt Interest Rate Ceiling Revere Lxrx
MortgageDebtInterestRateCeiling_Revere_LXRX
0.075
CY2018Q3 lxrx Mortgage Debt Interest Rate Base Revere Lxrx
MortgageDebtInterestRate_Base_Revere_LXRX
0.055
CY2018Q4 lxrx Mortgage Debt Issue Costs Revere Lxrx
MortgageDebtIssueCosts_Revere_LXRX
300000 USD
CY2018Q3 lxrx Mortgage Debt Issue Costs Revere Lxrx
MortgageDebtIssueCosts_Revere_LXRX
400000 USD
CY2015Q4 lxrx Research And Development Arrangement Contract To Perform For Others Number Of Development Milestones
ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfDevelopmentMilestones
4 milestone
CY2015Q4 lxrx Research And Development Arrangement Contract To Perform For Others Number Of Regulatory Milestones
ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfRegulatoryMilestones
4 milestone
CY2015Q4 lxrx Research And Development Arrangement Contract To Perform For Others Royalties Percentage
ResearchAndDevelopmentArrangementContractToPerformForOthersRoyaltiesPercentage
0.40
CY2016Q4 lxrx Number Of Positions Created Inception To Date
NumberOfPositionsCreatedInceptionToDate
1616 job
CY2018Q4 lxrx Options Outstanding Equity Incentive Plan
OptionsOutstandingEquityIncentivePlan
5953831 shares
CY2018Q4 lxrx Options Outstanding Non Employee Directors Equity Incentive Plan
OptionsOutstandingNonEmployeeDirectorsEquityIncentivePlan
198551 shares
CY2015Q4 lxrx Research And Development Arrangement Contract To Perform For Others Commercial Costs Funded Percentage
ResearchAndDevelopmentArrangementContractToPerformForOthersCommercialCostsFundedPercentage
0.40
CY2015Q4 lxrx Research And Development Arrangement Contract To Perform For Others Development Costs Period
ResearchAndDevelopmentArrangementContractToPerformForOthersDevelopmentCostsPeriod
P3Y
CY2015Q4 lxrx Research And Development Arrangement Contract To Perform For Others Expiration Period
ResearchAndDevelopmentArrangementContractToPerformForOthersExpirationPeriod
P10Y
CY2015Q4 lxrx Research And Development Arrangement Contract To Perform For Others Number Of Commercial Milestones
ResearchAndDevelopmentArrangementContractToPerformForOthersNumberOfCommercialMilestones
6 milestone
CY2018Q4 lxrx Restricted Stock Units Outstanding Equity Incentive Plan
RestrictedStockUnitsOutstandingEquityIncentivePlan
1285752 shares
CY2015Q4 lxrx Sanofi Commercialization Costs Fundedby Lexicon Maximum Amount
SanofiCommercializationCostsFundedbyLexiconMaximumAmount
100000000 USD
CY2015Q4 lxrx Sanofi Development Milestones
SanofiDevelopmentMilestones
110000000 USD
CY2015Q4 lxrx Sanofi Outcomes Study Milestone
SanofiOutcomesStudyMilestone
100000000 USD
CY2015Q4 lxrx Sanofi Regulatory Milestones
SanofiRegulatoryMilestones
220000000 USD
CY2015Q4 lxrx Sanofi Revenue Allocatedto Development Deliverable
SanofiRevenueAllocatedtoDevelopmentDeliverable
113800000 USD
CY2015Q4 lxrx Sanofi Revenue Allocatedto Funding Deliverable
SanofiRevenueAllocatedtoFundingDeliverable
59400000 USD
CY2015Q4 lxrx Sanofi Revenue Allocatedto License Deliverable
SanofiRevenueAllocatedtoLicenseDeliverable
126800000 USD
CY2016 lxrx Sanofi Revenue Recognized
SanofiRevenueRecognized
71300000 USD
CY2017 lxrx Sanofi Revenue Recognized
SanofiRevenueRecognized
60100000 USD
CY2018 lxrx Sanofi Revenue Recognized
SanofiRevenueRecognized
33200000 USD
CY2015Q4 lxrx Sanofi Sales Milestone Payments
SanofiSalesMilestonePayments
990000000 USD
CY2016 lxrx Sanofi Salesof Clinical Trial Materials
SanofiSalesofClinicalTrialMaterials
6300000 USD
CY2017 lxrx Sanofi Salesof Clinical Trial Materials
SanofiSalesofClinicalTrialMaterials
1900000 USD
CY2015Q4 lxrx Sanofi Upfront Payment
SanofiUpfrontPayment
300000000 USD
CY2018 lxrx Sanofirevenuefromfilingperformance Lxrx
Sanofirevenuefromfilingperformance_LXRX
8600000 USD
CY2016 lxrx Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
11456 shares
CY2017 lxrx Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
10248 shares
CY2018 lxrx Share Based Compensation Arrangement By Share Based Payment Award Stock Bonus And Restricted Stock Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardStockBonusAndRestrictedStockGrantsInPeriod
20512 shares
CY2016 lxrx Sharebased Compensation Arrangementby Sharebased Payment Award Stock Bonusand Restricted Stockto Consultants Grantsin Period Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue
13.96
CY2017 lxrx Sharebased Compensation Arrangementby Sharebased Payment Award Stock Bonusand Restricted Stockto Consultants Grantsin Period Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue
15.61
CY2018 lxrx Sharebased Compensation Arrangementby Sharebased Payment Award Stock Bonusand Restricted Stockto Consultants Grantsin Period Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementbySharebasedPaymentAwardStockBonusandRestrictedStocktoConsultantsGrantsinPeriodWeightedAverageGrantDateFairValue
7.80
CY2018Q4 lxrx Shares Issued Pursuant To Restricted Stock Awards Non Employee Directors Equity Incentive Plan
SharesIssuedPursuantToRestrictedStockAwardsNonEmployeeDirectorsEquityIncentivePlan
103208 shares
CY2018Q4 lxrx Shares Issued Pursuant To Restricted Stock Units Equity Incentive Plan
SharesIssuedPursuantToRestrictedStockUnitsEquityIncentivePlan
1451648 shares
CY2018Q4 lxrx Shares Issued Pursuant To Stock Bonus Awards Equity Incentive Plan
SharesIssuedPursuantToStockBonusAwardsEquityIncentivePlan
113940 shares
CY2016 lxrx Shares Issued To Symphony Designees Value
SharesIssuedToSymphonyDesigneesValue
0 USD
CY2018 lxrx Shares Issued To Symphony Designees Value
SharesIssuedToSymphonyDesigneesValue
0 USD
CY2016 lxrx Stock Based Compensation Expense Associated With General And Administrative Expense
StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
3514000 USD
CY2017 lxrx Stock Based Compensation Expense Associated With General And Administrative Expense
StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
4567000 USD
CY2018 lxrx Stock Based Compensation Expense Associated With General And Administrative Expense
StockBasedCompensationExpenseAssociatedWithGeneralAndAdministrativeExpense
5686000 USD
CY2016 lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
3938000 USD
CY2017 lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
4905000 USD
CY2018 lxrx Stock Based Compensation Expense Associated With Research And Development Expense
StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense
6010000 USD
CY2018 lxrx Stock Option Exercise Price As Percent Of Value Of Common Stock
StockOptionExercisePriceAsPercentOfValueOfCommonStock
1.00
CY2018Q4 lxrx Stock Options Exercised Equity Incentive Plan
StockOptionsExercisedEquityIncentivePlan
1909515 shares
CY2018Q4 lxrx Stock Options Exercised Non Employee Directors Equity Incentive Plan
StockOptionsExercisedNonEmployeeDirectorsEquityIncentivePlan
0 shares
CY2010Q3 lxrx Symphon Fair Value Of Base And Contingent Payments
SymphonFairValueOfBaseAndContingentPayments
45600000 USD
CY2016Q3 lxrx Symphony Amendment Buyout
SymphonyAmendmentBuyout
21000000 USD
CY2010Q3 lxrx Symphony Base Payment Discount Rate
SymphonyBasePaymentDiscountRate
0.14
CY2012Q3 lxrx Symphony Base Payment In Shares
SymphonyBasePaymentInShares
1891074 shares
CY2012Q3 lxrx Symphony Base Payment Obligation
SymphonyBasePaymentObligation
35000000 USD
CY2010Q3 lxrx Symphony Contingent Payment Discount Rate
SymphonyContingentPaymentDiscountRate
0.18
CY2014Q4 lxrx Symphony Contingent Payment In Cash
SymphonyContingentPaymentInCash
5800000 USD
CY2015Q2 lxrx Symphony Contingent Payment In Cash
SymphonyContingentPaymentInCash
750000 USD
CY2016Q3 lxrx Symphony Contingent Payment In Cash
SymphonyContingentPaymentInCash
3200000 USD
CY2017Q1 lxrx Symphony Contingent Payment In Cash
SymphonyContingentPaymentInCash
10500000 USD
CY2017 lxrx Symphony Contingent Payment In Cash
SymphonyContingentPaymentInCash
10499000 USD
CY2010Q3 lxrx Symphony Contingent Payment Maximum
SymphonyContingentPaymentMaximum
45000000 USD
CY2010Q3 lxrx Symphony Contingent Payment Percentage
SymphonyContingentPaymentPercentage
0.50
CY2014Q4 lxrx Symphony Contingent Payment Total
SymphonyContingentPaymentTotal
11500000 USD
CY2014Q4 lxrx Symphony Contingent Paymentin Shares
SymphonyContingentPaymentinShares
666111 shares
CY2017Q1 lxrx Symphony Contingent Paymentin Shares
SymphonyContingentPaymentinShares
659905 shares
CY2010Q3 lxrx Symphony Icon Goodwill
SymphonyIconGoodwill
18700000 USD
CY2010Q3 lxrx Symphony Payment In Stock Limitation
SymphonyPaymentInStockLimitation
0.50
CY2010Q3 lxrx Symphony Regulatory Approval Payment
SymphonyRegulatoryApprovalPayment
15000000 USD
CY2010Q3 lxrx Symphony Regulatory Approval Percentage Limit
SymphonyRegulatoryApprovalPercentageLimit
0.50
CY2010Q3 lxrx Symphony Regulatory Approval Reduction Percentage
SymphonyRegulatoryApprovalReductionPercentage
0.50
CY2018Q4 lxrx Tigm Maximum Exposure
TigmMaximumExposure
14200000 USD
CY2018Q4 lxrx Tigm Per Job Payment Amount
TigmPerJobPaymentAmount
2415 USD
CY2018Q4 lxrx Total Shares That May Be Issued Equity Incentive Plan
TotalSharesThatMayBeIssuedEquityIncentivePlan
15000000 shares
CY2018Q4 lxrx Total Shares That May Be Issued Non Employee Directors Equity Incentive Plan
TotalSharesThatMayBeIssuedNonEmployeeDirectorsEquityIncentivePlan
600000 shares
CY2018Q4 lxrx Totalvalueofsharesbynonemployeeinayear
Totalvalueofsharesbynonemployeeinayear
500000 USD
CY2005Q3 lxrx Tx Enterprise Fund Award
TxEnterpriseFundAward
35000000 USD
CY2005Q3 lxrx Tx Enterprise Fund Award To Texas Am University System
TxEnterpriseFundAwardToTexasAmUniversitySystem
15000000 USD
lxrx Xermelo Intangible Assets Finite Lived
XERMELOIntangibleAssetsFiniteLived
24700000 USD
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
38762000 USD
CY2018Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
17759000 USD
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4825000 USD
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5924000 USD
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
12282000 USD
CY2018Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14482000 USD
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
58623000 USD
CY2018Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
60006000 USD
CY2017Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-222000 USD
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-12000 USD
CY2017Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1435526000 USD
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1447954000 USD
CY2016 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7452000 USD
CY2017 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9472000 USD
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
11696000 USD
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
4000 USD
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
4000 USD
CY2016 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
527000 USD
CY2017 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
599000 USD
CY2018 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1336000 USD
CY2017 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1500000 USD
CY2018 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1800000 USD
CY2016 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2017 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2018 us-gaap Asset Impairment Charges
AssetImpairmentCharges
0 USD
CY2017Q4 us-gaap Assets
Assets
436539000 USD
CY2018Q4 us-gaap Assets
Assets
284136000 USD
CY2017Q4 us-gaap Assets Current
AssetsCurrent
321995000 USD
CY2018Q4 us-gaap Assets Current
AssetsCurrent
173324000 USD
CY2017Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
249127000 USD
CY2018Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
79666000 USD
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
202989000 USD
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46600000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
61661000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
80386000 USD
CY2017Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
61661000 USD
CY2018Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
80386000 USD
CY2016 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-156389000 USD
CY2017 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
15061000 USD
CY2018 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
18725000 USD
CY2017Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000 shares
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
225000000 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
106000 USD
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
106000 USD
CY2016 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-131421000 USD
CY2017 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-123020000 USD
CY2018 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-120338000 USD
CY2016 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0 USD
CY2017 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1899000 USD
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
2491000 USD
CY2018Q4 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
8.442
CY2014Q4 us-gaap Debt Instrument Convertible Conversion Ratio1
DebtInstrumentConvertibleConversionRatio1
118.4553
CY2017Q4 us-gaap Debt Instrument Description
DebtInstrumentDescription
200000
CY2017Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
150000000 USD
CY2018Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
97500000 USD
CY2018Q4 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.09
CY2014Q4 us-gaap Debt Instrument Term
DebtInstrumentTerm
P7Y
CY2017Q4 us-gaap Debt Instrument Term
DebtInstrumentTerm
P5Y
CY2018Q3 us-gaap Debt Instrument Term
DebtInstrumentTerm
P2Y
CY2018Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
3200000 USD
CY2017Q4 us-gaap Deferred Finance Costs Gross
DeferredFinanceCostsGross
4100000 USD
CY2018Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
4913000 USD
CY2016 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2017 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-12661000 USD
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0 USD
CY2017Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
10897000 USD
CY2018Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
10527000 USD
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
40351000 USD
CY2018Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3395000 USD
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
24903000 USD
CY2018Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
23651000 USD
CY2017Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
13523000 USD
CY2018Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
5458000 USD
CY2017Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
346642000 USD
CY2017Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
68603000 USD
CY2018Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
71047000 USD
CY2017Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
183839000 USD
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
206789000 USD
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
455800000 USD
CY2017Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
5656000 USD
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
6044000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
46574000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
47087000 USD
CY2017Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
3923000 USD
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4641000 USD
CY2017Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
341759000 USD
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
364702000 USD
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
369215000 USD
CY2017Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
6014000 USD
CY2018Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
6014000 USD
CY2017Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
6014000 USD
CY2018Q4 us-gaap Deferred Tax Liabilities Noncurrent
DeferredTaxLiabilitiesNoncurrent
6014000 USD
CY2017Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
1000 USD
CY2018Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
2000 USD
CY2016 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
700000 USD
CY2017 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1000000 USD
CY2018 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
1000000 USD
CY2016 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2056000 USD
CY2017 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3399000 USD
CY2018 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3683000 USD
CY2016 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.27
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.31
CY2017Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.28
CY2017Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.17
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.40
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.26
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.16
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.14
CY2018Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
22300000 USD
CY2018 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y2M
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-703000 USD
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
2101000 USD
CY2017 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
-3200000 USD
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
-21013000 USD
CY2016Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
22815000 USD
CY2017Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
18912000 USD
CY2018Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
0 USD
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
12654000 USD
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1766000 USD
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
1766000 USD
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
1766000 USD
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
1766000 USD
CY2018Q4 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
1766000 USD
CY2018Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
21484000 USD
CY2016 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-16000 USD
CY2017 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-3000 USD
CY2018 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
0 USD
CY2018Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0 USD
CY2016 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
43157000 USD
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
66090000 USD
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
63754000 USD
CY2017Q4 us-gaap Goodwill
Goodwill
44543000 USD
CY2018Q4 us-gaap Goodwill
Goodwill
44543000 USD
CY2016 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2017 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2018 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
CY2016 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 USD
CY2017 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 USD
CY2018 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
0 USD
CY2016 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-131445000 USD
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-135654000 USD
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-120548000 USD
CY2016 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
13584000 USD
CY2017 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-11875000 USD
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-18857000 USD
CY2016 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
4080000 USD
CY2017 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-166000 USD
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1099000 USD
CY2016 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-69262000 USD
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-51133000 USD
CY2018 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-23996000 USD
CY2016 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0 USD
CY2017 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1948000 USD
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2732000 USD
CY2016 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
32000 USD
CY2017 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-33000 USD
CY2018 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-144000 USD
CY2016 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-6259000 USD
CY2017 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
557000 USD
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1766000 USD
CY2016 us-gaap Interest Expense
InterestExpense
6567000 USD
CY2017 us-gaap Interest Expense
InterestExpense
6984000 USD
CY2017 us-gaap Interest Paid Net
InterestPaidNet
5870000 USD
CY2018 us-gaap Interest Expense
InterestExpense
20777000 USD
CY2016 us-gaap Interest Paid Net
InterestPaidNet
6050000 USD
CY2018 us-gaap Interest Paid Net
InterestPaidNet
16465000 USD
CY2017Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1183000 USD
CY2018Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
884000 USD
CY2017Q4 us-gaap Inventory Gross
InventoryGross
1948000 USD
CY2018Q4 us-gaap Inventory Gross
InventoryGross
4680000 USD
CY2017Q4 us-gaap Inventory Net
InventoryNet
1948000 USD
CY2018Q4 us-gaap Inventory Net
InventoryNet
4680000 USD
CY2017Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
616000 USD
CY2018Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
3564000 USD
CY2017Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
149000 USD
CY2018Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
232000 USD
CY2017Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
310788000 USD
CY2018Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
160052000 USD
CY2016 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
500000 USD
CY2017 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
600000 USD
CY2018 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
600000 USD
CY2017Q4 us-gaap Liabilities
Liabilities
368274000 USD
CY2018Q4 us-gaap Liabilities
Liabilities
310541000 USD
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
436539000 USD
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
284136000 USD
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
105489000 USD
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
36751000 USD
CY2018Q4 us-gaap Long Term Debt
LongTermDebt
249915000 USD
CY2017Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
14094000 USD
CY2018Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
1115000 USD
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal After Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
0 USD
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
1285000 USD
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
0 USD
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
150000000 USD
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
87500000 USD
CY2018Q4 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
11130000 USD
CY2017Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
231576000 USD
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
243887000 USD
CY2018Q4 us-gaap Mortgage Loans On Real Estate
MortgageLoansOnRealEstate
12100000 USD
CY2016 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
987000 USD
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
149933000 USD
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2244000 USD
CY2016 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
18252000 USD
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
50522000 USD
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
169576000 USD
CY2016 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-175628000 USD
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-185394000 USD
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-148607000 USD
CY2016 us-gaap Net Income Loss
NetIncomeLoss
-131445000 USD
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-31918000 USD
CY2017Q4 us-gaap Net Income Loss
NetIncomeLoss
-26609000 USD
CY2017 us-gaap Net Income Loss
NetIncomeLoss
-122993000 USD
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-41822000 USD
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-34549000 USD
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-27396000 USD
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-16781000 USD
CY2017Q2 us-gaap Net Income Loss
NetIncomeLoss
-34657000 USD
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-29809000 USD
CY2017Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-29016000 USD
CY2018Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
285000 USD
CY2016 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
24000 USD
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-130624000 USD
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-37713000 USD
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-120548000 USD
CY2017 us-gaap New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification
NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
0 USD
CY2018 us-gaap New Accounting Pronouncement Or Change In Accounting Principle Effect Of Adoption Quantification
NewAccountingPronouncementOrChangeInAccountingPrincipleEffectOfAdoptionQuantification
14212000 USD
CY2018 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2016 us-gaap Operating Expenses
OperatingExpenses
206427000 USD
CY2017 us-gaap Operating Expenses
OperatingExpenses
222313000 USD
CY2018 us-gaap Operating Expenses
OperatingExpenses
166488000 USD
CY2016 us-gaap Operating Income Loss
OperatingIncomeLoss
-127171000 USD
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-39512000 USD
CY2017Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-33491000 USD
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-28605000 USD
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-30272000 USD
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22927000 USD
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-12367000 USD
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-103279000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2598000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
657000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
0 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
658000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
646000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
637000 USD
CY2018Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
0 USD
CY2018Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
941900000 USD
CY2017Q4 us-gaap Other Assets Current
OtherAssetsCurrent
4434000 USD
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2668000 USD
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
429000 USD
CY2017 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-27000 USD
CY2017 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1954000 USD
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
3508000 USD
CY2014Q4 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
3400000 USD
CY2016 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
621000 USD
CY2017 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1679000 USD
CY2018 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
972000 USD
CY2016 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
425673000 USD
CY2017 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
267873000 USD
CY2018 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
119987000 USD
CY2018 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
210000 USD
CY2017Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
51885000 USD
CY2018Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
50119000 USD
CY2017Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
292000 USD
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
238000 USD
CY2016 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2293000 USD
CY2016 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
231000 USD
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
228000 USD
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
95000 USD
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q4 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
87500000 USD
CY2016 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3624000 USD
CY2017 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7987000 USD
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
732000 USD
CY2016 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
CY2017 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
145905000 USD
CY2018 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
12529000 USD
CY2016 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
444156000 USD
CY2017 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
318623000 USD
CY2018 us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
289658000 USD
CY2016 us-gaap Profit Loss
ProfitLoss
-131445000 USD
CY2017 us-gaap Profit Loss
ProfitLoss
-122993000 USD
CY2018 us-gaap Profit Loss
ProfitLoss
-120548000 USD
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
76310000 USD
CY2018Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
75871000 USD
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17687000 USD
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
15865000 USD
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
152223000 USD
CY2018 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
36271000 USD
CY2018Q3 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P10Y
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
100243000 USD
CY2016 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1365241000 USD
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1471577000 USD
CY2017 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
7000 USD
CY2018 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0 USD
CY2016 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0 USD
CY2016 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2016000 USD
CY2017 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
15890000 USD
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
26583000 USD
CY2016 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
79101000 USD
CY2017 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
75621000 USD
CY2017 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2280000 USD
CY2018 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
14533000 USD
CY2016 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
163973000 USD
CY2016 us-gaap Revenues
Revenues
79256000 USD
CY2017Q1 us-gaap Revenues
Revenues
17962000 USD
CY2017Q2 us-gaap Revenues
Revenues
12087000 USD
CY2017Q3 us-gaap Revenues
Revenues
27674000 USD
CY2017Q4 us-gaap Revenues
Revenues
33966000 USD
CY2017 us-gaap Revenues
Revenues
91689000 USD
CY2018Q1 us-gaap Revenues
Revenues
25374000 USD
CY2018Q2 us-gaap Revenues
Revenues
13798000 USD
CY2018Q3 us-gaap Revenues
Revenues
6966000 USD
CY2018Q4 us-gaap Revenues
Revenues
17071000 USD
CY2018 us-gaap Revenues
Revenues
63209000 USD
CY2016 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
155000 USD
CY2017 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
178000 USD
CY2018 us-gaap Royalty Income Nonoperating
RoyaltyIncomeNonoperating
355000 USD
CY2016 us-gaap Share Based Compensation
ShareBasedCompensation
7452000 USD
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
9472000 USD
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
11696000 USD
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
7438134 shares
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
4583555 shares
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1700000 USD
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2000000 USD
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000 USD
CY2016 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.43
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.59
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.63
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
300000 USD
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
300000 USD
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y2M
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y7M
CY2017Q4 us-gaap Short Term Investments
ShortTermInvestments
249127000 USD
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
79666000 USD
CY2016 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
6125000 USD
CY2016Q4 us-gaap Stockholders Equity
StockholdersEquity
167507000 USD
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
68265000 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-26405000 USD
CY2017Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
122000 shares
CY2018Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
236000 shares
CY2017 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
5486000 USD
CY2018 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
732000 USD
CY2017Q4 us-gaap Treasury Stock Value
TreasuryStockValue
1904000 USD
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2876000 USD
CY2017 us-gaap Stock Issued During Period Value Treasury Stock Reissued
StockIssuedDuringPeriodValueTreasuryStockReissued
0 USD
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
285972000 USD
CY2016 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
621000 USD
CY2017 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
1679000 USD
CY2018 us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
972000 USD
CY2018Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
1400000 USD
CY2016 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
24000 USD
CY2017 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-27000 USD
CY2018 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
210000 USD
CY2017Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0 USD
CY2018 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
-22900000 USD
CY2016 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
103863000 shares
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
104461000 shares
CY2017Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
105300000 shares
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
105582000 shares
CY2017Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
105588000 shares
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
105237000 shares
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
105668000 shares
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
105848000 shares
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
105881000 shares
CY2018Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
105920000 shares
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
105830000 shares
CY2018 us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates:</font><font style="font-family:inherit;font-size:10pt;"> The preparation of financial statements in conformity with U. S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</font></div></div>

Files In Submission

Name View Source Status
0001062822-19-000007-index-headers.html Edgar Link pending
0001062822-19-000007-index.html Edgar Link pending
0001062822-19-000007.txt Edgar Link pending
0001062822-19-000007-xbrl.zip Edgar Link pending
exh101coatsofferletteramen.htm Edgar Link pending
exh1023amendno1catalentcom.htm Edgar Link pending
exh1024amendno2catalentcom.htm Edgar Link pending
exh104-santiniofferlettera.htm Edgar Link pending
exh1092017non-employeedire.htm Edgar Link pending
exh231ernst_youngconsent10.htm Edgar Link pending
exh311certificationofprinc.htm Edgar Link pending
exh312certificationofprinc.htm Edgar Link pending
exh321certificationofprinc.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
form10k12312018.htm Edgar Link pending
image32.jpg Edgar Link pending
lxrx-20181231.xml Edgar Link completed
lxrx-20181231.xsd Edgar Link pending
lxrx-20181231_cal.xml Edgar Link unprocessable
lxrx-20181231_def.xml Edgar Link unprocessable
lxrx-20181231_lab.xml Edgar Link unprocessable
lxrx-20181231_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending